Molecule to Market: Inside the outsourcing space

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development and commercialisation lifecycle with Kevin Jones, CEO of Aliri Bioanalysis.

 

Your host, Raman Sehgal, discusses the pharma and biopharma ecosystem with Kevin, covering:

His journey from working nights in the lab to leading global commercial and scientific teams

Why flexibility, care and a consultative approach are critical differentiators for smaller specialist CROs competing against one stop shop providers

What attracted him to Aliri Bioanalysis, and the appeal of joining a fast growing, private equity backed business, something he had not previously experienced

How the role and perception of CROs has evolved over the last 30 years, including Kevin’s five principles for what clients value when selecting partners today

How the market has begun to rebound after a difficult few years, and why he believes the industry is entering a new molecule renaissance

 

Kevin Jones is CEO of Aliri Bioanalysis, a contract research organisation supporting drug developers with regulated bioanalysis and PK/TK testing. He began his career running laboratories and has spent three decades leading large, multidisciplinary scientific teams across both GMP and GLP/clinical environments.

 

Kevin previously led Global Bioanalysis at Covance, now Labcorp, and served as Vice President and General Manager of Bioanalytical/ADME, Vaccine and Discovery Laboratories at Q² Solutions, part of IQVIA. His experience spans laboratory operations, global integration and strategic growth, with a particular focus on building service organisations that scale without compromising quality or the client experience.

 

Connect with him on LinkedIn.

 

 

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

 

Ben Locwin, Senior VP at Reliant Life Sciences

Jennifer Chadwick, Founder at Jennifer Chadwick Consulting LLC

Jeff Buguliskis, Deputy Chief Editor at Outsourced Pharma

 

Your host, Raman Sehgal, discusses the takeaways from CDMO with his guests on a live panel from Boston. The event was hosted by PharmaSource and Molecule to Market.

 

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this special encore episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Thomas Eldered, Executive Chairman of Flerie.

Your host, Raman Sehgal, revisits one of Molecule to Market’s most fascinating founder stories, bringing together Thomas’ original two part conversation into one episode charting the journey from a small Swedish contract manufacturer to a global CDMO powerhouse.

Raman and Thomas discuss the pharmaceutical and biotechnology supply chain, covering:

How a series of failed plans eventually led to the creation of a CMO before the term was widely used

Building Recipharm from a local Swedish manufacturer into an international CDMO employing more than 9,000 people across 10 countries

Why having cash during the financial crash created an opportunity to accelerate growth through M&A

The decision to take Recipharm public when very few Swedish businesses, and virtually no CDMOs, were pursuing an IPO

Why selling Recipharm after 26 years was one of the hardest decisions of his career

How the divestment of Cobra Biologics led Thomas back into ownership, and how the gene therapy boom transformed the fortunes of the business

Choosing passion rather than pension after his exits, and continuing to build and invest through Flerie

The mindset, timing and calculated risk taking behind one of the most remarkable journeys in the CDMO sector

 

Thomas Eldered co-founded Recipharm in 1995 and helped grow the company from a local Swedish contract manufacturer into one of the world’s leading CDMOs before leaving the business in 2021.

He founded Flerie in 2011 and today serves as Executive Chairman. Flerie is a long term life science investor focused on developing companies built around scientific innovation and unmet medical needs. Thomas also serves as chairman and board member across a number of life science businesses. (Flerie)

Thomas holds an MSc in Industrial Engineering and Management from Linköping University.

Connect with him on LinkedIn.

 

Molecule to Market is sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Live from CPHI Milan, Molecule to Market and ramarketing bring together 11 senior leaders from across the global pharma outsourcing sector to tackle some of the industry's biggest trade-offs. 

 

In this special episode, produced in partnership with ramarketing, host Raman Sehgal cuts through the usual industry talking points with a series of rapid-fire, either-or questions designed to uncover what leaders are really prioritizing, where opinions align, and where perspectives differ.

 

From balancing cost with flexibility to weighing technology against human expertise, we explore the decisions shaping the future of pharma services, what customers value most, and where the industry could be heading over the next five years.

 

Expect different perspectives, some tough choices, and plenty of food for thought from the people helping shape the future of pharma outsourcing.

 

Featuring insights from:

Maja Pedersen, President and COO at Fujifilm Biotechnologies

Hayley Crowe, Executive VP and General Manager of Global Life Sciences at Ecolab

John Wichelt, VP/General Manager at Kindeva

Henning Steinhagen, CEO at Symeres

Campbell Bunce, Chief Scientific Officer at Abzena

Patrick Kelley, Senior Director - Commercial at Pace Life Sciences

Matt Peterson, Chief Strategy Officer at Quotient Sciences

Joe Lipari, Director, Global Traceability Solutions at Systech

Martin Meeson, CEO at Axplora

Darren Hieber, VP of Alliance Partnerships at Ensera Pharma/Design

Luke Guerrero, Co-Founder & Director of Operations at Digital CMC Consortium 

 

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

 

Bobby Sheng, Chairman and CEO of Bora Pharmaceuticals

Derek Hennecke, Biotech Entrepreneur and Board Member

Maja Herold Pedersen, President and COO of Fujifilm Biotechnologies

 

Your host, Raman Sehgal, discusses the real truths shaping pharma outsourcing with his guests live from CPHI Milan 2026. The event was hosted by Ramarketing and Molecule to Market.

 

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!